Blog
RSS FeedPosted by Michael Wonder on 05 Mar 2020
NICE pushes Doptelet for pre-surgery liver disease treatment
5 March 2020 - NICE has published a new final draft guidance recommending Dova Pharmaceuticals’ Doptelet (avatrombopag) for thrombocytopenia - ...
Posted by Michael Wonder on 27 Feb 2020
NICE recommends new ‘chemotherapy-free’ treatment for lymphoma
27 February 2020 - A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been ...
Posted by Michael Wonder on 26 Feb 2020
Polivy struck by NICE ‘no’
26 February 2020 - The National Institute for Health and Care Excellence has announced that it does not recommend Polivy ...
Posted by Michael Wonder on 04 Feb 2020
Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine
4 February 2020 - NICE has today published the outcome of the appeal against its final draft guidance on erenumab (Aimovig; ...
Posted by Michael Wonder on 03 Feb 2020
Rinvoq NICE approval could benefit 54,000 people
3 February 2020 - The National Institute for Health and Care Excellence has announced a new draft guidance recommending Abbvie’s ...
Posted by Michael Wonder on 22 Jan 2020
NHS patients denied new lung cancer drug after another NICE deadlock
22 January 2020 - Certain untreated lung cancer patients on England’s NHS will have to make do with older drugs ...
Posted by Michael Wonder on 22 Jan 2020
NICE rejects Janssen’s Stelara on cost efficiency grounds
22 January 2020 - NICE has released a draft guidance not recommending Janssen’s Stelara (ustekinumab) for moderately to severely active ...
Posted by Michael Wonder on 17 Jan 2020
NICE encourages further data collection on ‘game changing’ histology independent cancer drugs
17 January 2020 - Larotrectinib (also called Vitrakvi and made by Bayer), a new treatment for a range of cancers, can’t ...
Posted by Michael Wonder on 16 Jan 2020
NICE ‘OK’ for Lynparza
16 January 2020 - NICE has recommended MSD and AstraZeneca’s Lynparza (olaparib) tablets, for adults who have relapsed platinum-sensitive ovarian, ...
Posted by Michael Wonder on 16 Jan 2020
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
15 January 2020 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...
Posted by Michael Wonder on 04 Jan 2020
NICE refuses Akcea’s Waylivra
3 January 2020 - NICE has issued an Evaluation Consultation Document, refusing Waylivra (volanesorsen) as a treatment for familial chylomicronaemia ...
Posted by Michael Wonder on 16 Dec 2019
NICE u-turn backs NHS use of Veltassa
16 December 2019 - The National Institute for Health and Care Excellence has given its stamp of approval for NHS ...
Posted by Michael Wonder on 12 Dec 2019
NICE and the SMC have published recommendations on Shionogi’s Mulpleo (lusutrombopag), approving its use for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
12 December 2019 - Mulpleo (lusutrombopag) is the first licensed treatment to be made available through the National Health Service ...
Posted by Michael Wonder on 02 Dec 2019
NICE grants Lynparza expansion for advanced ovarian cancer
2 December 2019 - Lynparza (olaparib), the joint MSD and AstraZeneca cancer drug, has been granted an expansion by NICE ...
Posted by Michael Wonder on 28 Nov 2019
Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund
28 November 2019 - Around 3,200 women in England could be eligible for treatment. ...